A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients

Administration of first-in-class anti-EGFR monoclonal antibody cetuximab is contingent upon extensive pharmacogenomic testing. However in addition to tumor genomics, drug exposure levels could play a critical, yet largely underestimated role, because several reports have demonstrated that cetuximab...

Descripción completa

Detalles Bibliográficos
Autores principales: Becher, François, Ciccolini, Joseph, Imbs, Diane-Charlotte, Marin, Clémence, Fournel, Claire, Dupuis, Charlotte, Fakhry, Nicolas, Pourroy, Bertrand, Ghettas, Aurélie, Pruvost, Alain, Junot, Christophe, Duffaud, Florence, Lacarelle, Bruno, Salas, Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457398/
https://www.ncbi.nlm.nih.gov/pubmed/28578404
http://dx.doi.org/10.1038/s41598-017-02821-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457398/
https://www.ncbi.nlm.nih.gov/pubmed/28578404
http://dx.doi.org/10.1038/s41598-017-02821-x

Ejemplares similares